Skip to main content

Advertisement

Table 2 Achieving fixed targets: the annual number of susceptible PWID who must be vaccinated for every reduction in treatments administered in order to maintain a specified reduction in prevalence

From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

   75 % relative prevalence reduction target 50 % relative prevalence reduction target 25 % relative prevalence reduction target
Time to target (years) 10 15 30 10 15 30 10 15 30
  25 % initial chronic HCV prevalence among PWID
Vaccine efficacy 90 % 17.7 13.9 8.5 14.1 10.4 6.7 11.2 8.0 5.6
60 % 26.8 21.3 14.1 21.2 15.5 10.0 17.0 12.1 8.5
30 % 60.9 41.6 38.1 41.9 30.8 20.0 34.9 24.6 16.9
50 % initial chronic HCV prevalence among PWID
90 % 5.8 4.3 2.9 4.3 3.2 2.1 3.4 2.4 1.6
60 % 8.6 6.3 4.3 6.5 4.8 3.2 5.1 3.7 2.4
30 % 17.2 13.0 8.9 13.0 9.7 6.5 10.3 7.5 4.9
75 % initial chronic HCV prevalence among PWID
90 % 2.0 1.4 1.0 1.4 1.0 0.7 1.1 0.8 0.5
60 % 3.0 2.1 1.5 2.2 1.5 1.0 1.6 1.1 0.8
30 % 5.6 4.3 2.9 4.3 3.1 2.1 3.2 2.3 1.5
  1. HCV hepatitis C virus, PWID people who inject drugs